This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

Gestur Vidarsson, PhD
Head of Immunoglobulin Research/PI, Experimental Immunohematology at Sanquin Research

Profile

Dr. Vidarsson is a principle investigator at the Department of Experimental Immunohematology and head of the Immunoglobulin Research laboratory at Sanquin Research, in conjunction with the Landsteiner Laboratory – a part of the Amsterdam University Medical Center. He holds a BSc in molecular biology and an MSc in Immunology from the University of Iceland, and obtained his doctorate from the Department of Immunology, University Medical Center Utrecht (UMCU) in 2000. He completed postdoctoral fellowships at UMCU’s Eijkman Graduate School for Immunology and Infectious Diseases; the Vaccine Research Laboratory at the Netherlands Vaccine Institute, Bilthoven; and the Department of Experimental Immunohematology, Sanquin Research and Landsteiner Laboratory.

Dr Vidarsson’s research focus is on immune responses, from B cells to phagocytes. In particular, his research emphasizes on understanding antibody biology, through observations of human immune responses and experimentation by antibody engineering. Since 2008 his team increasingly focused on altered antibody glycosylation in human immune responses, through which his group played a leading role uncovering that IgG-glycosylation can be fundamentally altered in some immune responses having strong clinical consequences. To decipher the meaning of antibody glycosylation for complement- and/or Fc-receptor functions, his group also set up unique glycoengineering tools that have uncovered their functional significance. These tools are now being put to use by his team to improve screening of pathological antibodies in pregnancy, and for various other applications in infectious diseases and cancer immunology through various collaborations.

According to Google scholar, his work has been cited >4800 times yielding a h-index of 38, with 59 papers cited more than 10 times in the last 5 years. He received a European Community Biotechnology program grant enabling his own PhD project, has among other intramural Sanquin grants, been awarded five times with grants from the “Landsteiner Stichting voor Bloedtransfusie Research” (LSBR) (>2 M€) and was a co-applicant for an NWO Investment subsidy in 2012 (0.47 M€). His work has led to several collaborations with biopharma and currently has one post doc and one PhD student financed through his connections with Genmab (Netherlands) and Argenx (Belgium). He has supervised 10 PhD students successfully completing their defense, and is currently (co) supervising 6 PhD students), 3 technicians and one post docs.

Agenda Sessions

  • LIVE Moderated Panel Discussion and Q&A Including Audience Interaction with Speakers from On-Demand SESSION #6: MODIFYING FC INTERACTIONS TO ENHANCE ANTIBODY THERAPIES - To prepare for this discussion/Q&A, attendees should view the presentations from Session #6 in the Watch On-Demand Sessions Tab prior to this session

    11:15
  • Regulation of NK Cell-mediated ADCC: Implications for Therapeutic Antibodies

    On Demand